Central Nervous System Lymphoma
📧 Sign up to get email alerts when something new happens for Central Nervous System Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-04-27Clinical Trial Update: Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma [NA]
Clinical trial update noting ongoing recruitment for a regimen of rituximab, methotrexate, and thiotepa induction followed by etoposide and …
-
CLINICAL_TRIALS other · 2025-04-24Clinical Trial Update: DALY II USA/ MB-CART2019.1 for DLBCL [Phase 2]
Miltenyi Biomedicine's MB-CART2019.1 (DALY II) is in Phase 2 for refractory/relapsed B-cell lymphomas, including Diffuse Large B-Cell Lympho…
-
CLINICAL_TRIALS research · 2025-04-23Clinical Trial Update: Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104) [Phase 2]
A Phase 2 clinical trial evaluating tirabrutinib as maintenance therapy versus placebo in patients with primary central nervous system lymph…
-
CLINICAL_TRIALS research · 2025-04-23Clinical Trial Update: Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating a four-drug combination (rituximab, lenalidomide, methotrexate, and temozolomide) for primary central…
-
CLINICAL_TRIALS other · 2025-04-23Clinical Trial Update: Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma [Phase 2]
A Phase 2 trial is investigating the combination of orelabrutinib and pemetrexed for relapsed/refractory central nervous system lymphoma and…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-04-16Clinical Trial Update: A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas [Phase 1, Phase 2]
Clinical trial update on a Phase I/II study evaluating the safety of autologous CD20 CAR-T cells in relapsed or refractory B-cell non-Hodgki…
-
CLINICAL_TRIALS trial_result · 2025-04-09Clinical Trial Update: A Nomogram for Predicting the Diagnosis of Central Malignant Tumors Based on Preoperative Clinical Characteristics and Laboratory Indicators:
A completed clinical trial evaluates a nomogram based on preoperative clinical characteristics and laboratory indicators to predict diagnose…
-
CLINICAL_TRIALS research · 2025-03-30Clinical Trial Update: Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients [Phase 2]
A Phase 2 clinical trial is evaluating methotrexate or thiotepa in combination with R-CHOP and orelabrutinib for central nervous system lymp…
-
CLINICAL_TRIALS research · 2025-03-14Clinical Trial Update: Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma [Phase 2]
This clinical trial update describes a Phase 2 study of Relma-cel followed by Tislelizumab for relapsed/refractory central nervous system ly…
-
CLINICAL_TRIALS trial_result · 2025-02-28Clinical Trial Update: Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma [Phase 2]
Phase 2 clinical trial update evaluating the combination of Nivolumab and Ibrutinib in relapsed or refractory central nervous system lymphom…
-
CLINICAL_TRIALS research · 2025-02-18Clinical Trial Update: Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL [NA]
Clinical trial update for a Rituximab-Methotrexate-Temozolomide-Thiotepa regimen as first-line therapy for primary central nervous system ly…
-
CLINICAL_TRIALS research · 2025-02-17Clinical Trial Update: Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients [Phase 3]
Phase 3 clinical trial comparing adjusted high-dose chemotherapy with autologous stem cell transplant versus conventional immunochemotherapy…
-
CLINICAL_TRIALS research · 2025-02-03Clinical Trial Update: Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating tafasitamab plus lenalidomide for relapsed central nervous system lymphomas is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2025-01-30Clinical Trial Update: Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System [Phase 2]
A Phase 2 trial investigating tailored treatment for elderly patients with newly diagnosed primary central nervous system lymphoma has compl…
-
CLINICAL_TRIALS research · 2025-01-13Clinical Trial Update: [90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating [90Y]Y-PTT Endoradiotherapy for primary central nervous system lymphoma is currently recruiting, sponsor…
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients [EARLY_Phase 1]
Early-phase 1 clinical trial evaluating autologous CD19-CD22 targeted T cells in patients with refractory or relapsed central nervous system…
-
CLINICAL_TRIALS trial_result · 2025-01-06Clinical Trial Update: A Phase I/II Study to Investigate the Use of VORAXAZE™ As Intended Intervention in Patients with CNSL [Phase 1, Phase 2]
This clinical trial update reports the completion of a Phase I/II study evaluating VORAXAZE for central nervous system lymphoma.
-
CLINICAL_TRIALS research · 2025-01-01Clinical Trial Update: CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01)
This clinical trial update describes the NLG-PCNSL-01 study evaluating circulating tumor DNA for early response assessment in primary centra…
-
CLINICAL_TRIALS research · 2024-12-17Clinical Trial Update: NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL [Phase 2]
A Phase 2 clinical trial evaluating NB02 (Poseltinib) in combination with Rituximab and Lenalidomide for relapsed/refractory Primary Central…
-
CLINICAL_TRIALS trial_result · 2024-12-10Clinical Trial Update: High-dose Sequential Chemoimmunotherapy for B-cell Lymphomas With Central Nervous System Involvement [Phase 2]
Phase 2 study evaluating high-dose sequential chemoimmunotherapy for B-cell lymphomas with central nervous system involvement has completed …
-
CLINICAL_TRIALS research · 2024-12-03Clinical Trial Update: Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan: a Nationwide Study
A nationwide real-world study in Taiwan assesses the effectiveness and safety of Tirabrutinib for relapsed or refractory Primary Central Ner…
-
CLINICAL_TRIALS trial_result · 2024-10-18Clinical Trial Update: A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL [Phase 1]
A dose-escalating Phase 1 pilot study of orelabrutinib in newly diagnosed primary central nervous system lymphoma is active but not recruiti…
-
CLINICAL_TRIALS trial_result · 2024-10-17Clinical Trial Update: High-dose Methotrexate Combined with Thiotepa and Zanubrutinib in the Treatment of Newly Diagnosed PCNSL (MTZ) [Phase 2]
A Phase 2 clinical trial is evaluating high-dose methotrexate in combination with thiotepa and zanubrutinib for newly diagnosed primary cent…
-
CLINICAL_TRIALS research · 2024-10-15Clinical Trial Update: Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) [Phase 2]
Phase 2 trial of camrelizumab for recurrent primary central nervous system lymphoma is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-10-03Clinical Trial Update: High-dose Chemotherapy with Thiotepa, Busulfan, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Central Nervous System Lymphoma [Phase 2]
Phase 2 clinical trial evaluating high-dose thiotepa, busulfan, and cyclophosphamide followed by autologous stem cell transplantation in Cen…